Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Idelalisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 29,868Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nat’s Generics Idelalisib Receives Approval in US
    Nat’s Generics Idelalisib Receives Approval in US

    17 Feb 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216921

    FDA
    17 Feb 2026
    Share Share
    Natco Pharma’s Generics Idelalisib Receives Approval in US
    Natco Pharma’s Generics Idelalisib Receives Approval in US

    17 Feb 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216921

    FDA
    17 Feb 2026
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Idelalisib.
    FDA Confirms Paragraph IV Patent Litigation for Idelalisib.

    05 May 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-idelalisib-1652172175.pdf

    FDA
    05 May 2022
    Share Share
    Incyte pulls approval filing, following Gilead out of the exitIn
    Incyte pulls approval filing, following Gilead out of the exitIn

    27 Jan 2022

    // N.P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/incyte-pulls-fda-filing-for-cancer-drug-approval-over-confirmatory-study-following-gilead

    N.P. Taylor FIERCEBIOTECH
    27 Jan 2022
    Share Share
    Gilead Withdraws Cancer Drug Amidst Uncompleted Follow-Up Trials
    Gilead Withdraws Cancer Drug Amidst Uncompleted Follow-Up Trials

    24 Jan 2022

    // Hayley Shasteen BIOSPACE

    https://www.biospace.com/article/gilead-withdraws-cancer-drug-amidst-uncompleted-follow-up-trials-/

    Hayley Shasteen BIOSPACE
    24 Jan 2022
    Share Share
    Gilead pulls 2 accelerated approval indications for cancer drug
    Gilead pulls 2 accelerated approval indications for cancer drug

    22 Jan 2022

    // Z. Brennan ENDPTS

    https://endpts.com/failing-to-confirm-clinical-benefit-gilead-pulls-2-accelerated-approval-indications-for-cancer-drug/

    Z. Brennan ENDPTS
    22 Jan 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.